A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

Table 2

Patients’ characteristics in two groups.

value	flu/Mel	flu/Cy/TBI
N	25	61
Age, median (range)	57 (35, 68)	61 (22, 75)	0.10
Male sex	11 (44%)	32 (52%)	0.64
Diagnosis			0.08
AML	11 (44%)	13 (21%)
ALL	4 (16%)	4 (7%)
MDS/MPS/CML	6 (24%)	14 (23%)
NHL/CLL/HD	3 (12%)	24 (39%)
PCD	1 (4%)	2 (3%)
Other	0 (0%)	4 (8%)
Cell source			<0.001
PBSC	25 (100%)	37 (61%)
BM	0 (0%)	24 (39%)
Patient CMV			0.38
Positive	18 (72%)	50 (82%)
Negative	7 (28%)	11 (18%)
ABO compatibility			0.32
Compatible	16 (64%)	33 (54%)
Incompatible minor	2 (8%)	15 (25%)
Incompatible minor and major	1 (4%)	2 (3%)
Incompatible major	6 (24%)	11 (18%)
DRI			0.06
Low	1 (4%)	7 (12%)
Intermediate	13 (52%)	27 (45%)
High/very high	11 (44%)	23 (38%)
CMl			0.09
1–3	11 (44%)	39 (64%)
4–8	14 (56%)	22 (36%)
Female donor male recipient	4 (16%)	8 (13%)	0.74